4886.T Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 Mai 2024 @ 08:15):

ASKA Pharmaceutical Holdings Co.,Ltd., through its subsidiaries, engages in the pharmaceutical, animal health, and hormone testing businesses in Japan...

Stats
Tagesvolumen	46 900.00
Durchschnittsvolumen	63 641.00
Marktkapitalisierung	64.22B
EPS	¥0 ( 2024-02-04 )
Nächstes Ertragsdatum	( ¥0 ) 2024-05-10
Last Dividend	¥8.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	9.97
ATR14	¥2.16 (0.10%)

Volumen Korrelation

Lang: 0.05 (neutral)

Kurz: -0.12 (neutral)

Signal:(39.06) Neutral

ASKA Pharmaceutical Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

ASKA Pharmaceutical Korrelation - Währung/Rohstoff

-0.70
( moderate negative )

-0.34
( neutral )

-0.54
( weak negative )

-0.83
( strong negative )

-0.25
( neutral )

-0.58
( weak negative )

ASKA Pharmaceutical Finanzdaten

Annual	2022
Umsatz:	¥60.46B
Bruttogewinn:	¥28.59B (47.28 %)
EPS:	¥150.08

FY	2022
Umsatz:	¥60.46B
Bruttogewinn:	¥28.59B (47.28 %)
EPS:	¥150.08

FY	2022
Umsatz:	¥56.61B
Bruttogewinn:	¥26.35B (46.55 %)
EPS:	¥151.22

Financial Reports:

No articles found.

ASKA Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥8.00 (N/A)	¥0 (N/A)	¥8.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

ASKA Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 3.89 - Decrease likely (22.11%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥7.00	2021-09-29
Last Dividend	¥8.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	¥31.00	--
Avg. Dividend % Per Year	0.00%	--
Score	3.32	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	3.89
Div. Directional Score	7.56	--

Next Divdend (Est)
(2024-07-03)

¥0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

3.32

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
9658.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
8600.T	Ex Dividend Junior	2023-09-28	Semi-Annually	0.00%
8182.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7564.T	Ex Dividend Knight	2024-03-28	Annually	0.00%
6768.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6104.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
4820.T	Ex Dividend Junior	2023-12-28	Semi-Annually	0.00%
4028.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
3245.T	Ex Dividend Junior	2023-09-28	Annually	0.00%
2270.T	Ex Dividend Junior	2024-03-28	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.105	1.500	7.90	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0687	1.200	7.71	9.25	[0 - 0.3]
returnOnEquityTTM	0.113	1.500	9.85	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	2.88	0.800	0.604	0.483	[1 - 3]
quickRatioTTM	1.797	0.800	4.14	3.31	[0.8 - 2.5]
cashRatioTTM	0.811	1.500	6.61	9.91	[0.2 - 2]
debtRatioTTM	0.107	-1.500	8.22	-10.00	[0 - 0.6]
interestCoverageTTM	130.07	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	204.81	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	204.81	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.167	-1.500	9.33	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.481	1.000	5.31	5.31	[0.2 - 0.8]
operatingProfitMarginTTM	0.0902	1.000	-0.197	-0.197	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.574	1.000	7.92	7.92	[0.2 - 2]
assetTurnoverTTM	0.654	0.800	8.97	7.18	[0.5 - 2]
Total Score				11.22

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	9.86	1.000	9.10	0	[1 - 100]
returnOnEquityTTM	0.113	2.50	9.91	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	204.81	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	1.764	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	204.81	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-13.08	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0935	1.000	-0.161	0	[0.1 - 0.5]
Total Score				3.89

ASKA Pharmaceutical

ASKA Pharmaceutical Holdings Co.,Ltd., through its subsidiaries, engages in the pharmaceutical, animal health, and hormone testing businesses in Japan. The company researches, develops, manufactures, and markets pharmaceutical products in the areas of endocrinology, obstetrics and gynecology, and urology; and manufactures, sells, imports, and exports veterinary medicines, veterinary medical devices, feed and feed additives, reagents, agrochemicals, industrial chemicals, hygiene products, and food products and their raw materials. It is also involved in the clinical examination and biological testing activities; and offers medical devices. The company was founded in 1920 and is headquartered in Tokyo, Japan.